Eurasian Hematology-Oncology Group

http://www.ehog.net/

 

Xth Eurasian Hematology-Oncology Congress
M

Sequencing Agents in the Management of EGFR+ NSCLC: Optimal 1st and 2nd Line IO Treatment Options + TKI Resistance Mechanisms

By Xth Eurasian Hematology-Oncology Congress FEATURING Mustafa Erman
By Xth Eurasian Hematology-Oncology Congress FEATURING Mustafa Erman
200 views
November 12, 2019
0 Comments
Login to view comments. Click here to Login

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
Lung
05:21
Xth Eurasian Hematology-Oncology Congress

Management of ALK+ NSCLC Through First and Subsequent Lines of Thera…

Feat. P. Yumuk
17:12
Xth Eurasian Hematology-Oncology Congress

Management of ALK+ NSCLC Through 1st and Subsequent Lines of Therapy…

Feat. P. Yumuk
20:50
Xth Eurasian Hematology-Oncology Congress

Sequencing Agents in the Management of EGFR+ NSCLC: TKI Optimal Trea…

Feat. M. Erman
08:26
Xth Eurasian Hematology-Oncology Congress

Sequencing Agents in the Management of EGFR+ NSCLC: Optimal 1st and …

Feat. M. Erman
05:02
Xth Eurasian Hematology-Oncology Congress

Anti-PD-1 / Anti-PD-L1 as Standard 2nd Line Treatment Improved OS in…

Feat. B. Uluc
14:47
Xth Eurasian Hematology-Oncology Congress

(DO NOT USE) Anti-PD-1 / Anti-PD-L1 in Newly Diagnosed Advanced NSCLC: Is …

Feat. B. Uluc
05:57
Xth Eurasian Hematology-Oncology Congress

1st, 2nd, 3rd Line & Maintenance IO Options in Locally Advanced …

Feat. B. Uluc